Search

Your search keyword '"Pedersen, Stephanie"' showing total 50 results

Search Constraints

Start Over You searched for: Author "Pedersen, Stephanie" Remove constraint Author: "Pedersen, Stephanie" Database Unpaywall Remove constraint Database: Unpaywall
50 results on '"Pedersen, Stephanie"'

Search Results

1. Figure S3 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA

2. Figure S1 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA

3. Figure S13 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA

5. Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA

6. Identification of intratumoral and peripheral T-cell receptor (TCR) repertoire features associated with acquired (Ar) and primary (Pr) resistance to immune checkpoint inhibitors (ICI).

7. Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab

8. Table TS6 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

9. Figure S1 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

10. Table TS4 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

11. Data from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

12. Table TS3 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

13. Table TS5 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

14. Table TS5 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

15. Table TS2 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

16. Table TS6 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

17. Table TS3 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

18. Figure S4 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

19. Table TS4 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

20. Abstract 6667: Pan-cancer assessment of tumour and peripheral T-cell receptor repertoire dynamics in patients treated with immune checkpoint inhibitors

21. Figure S5 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

22. Data from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

23. Table TS2 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

24. Table TS1 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

25. Figure S4 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

26. Figure S2 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

27. Figure S2 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

28. Figure S5 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

29. Figure S3 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

30. Figure S1 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

31. Table TS1 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

32. Figure S3 from Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma

33. Supplementary Table from EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression

34. Supplementary Figures from EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression

35. Supplementary Figures from EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression

36. Integrated, Longitudinal Analysis of Cell-Free DNA in Uveal Melanoma

37. Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma

38. Molecular classification of endometrial cancers using an integrative DNA sequencing panel (271)

39. Abstract 563: cfDNA-based analysis of minimal residual disease and T-cell receptor clonality as predictors of relapse in stage 3 NSCLC treated with chemoradiotherapy and durvalumab

40. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression

42. TCR clonality and Treg frequency as predictors of outcome in stage III NSCLC treated with durvalumab.

47. Counting animal species with DNA barcodes: Canadian insects

48. Biodiversity inventories in high gear: DNA barcoding facilitates a rapid biotic survey of a temperate nature reserve

50. Quantitative trait loci for precocious parr maturation, early smoltification, and adult maturation in double-backcrossed trans-Atlantic salmon (Salmo salar)

Catalog

Books, media, physical & digital resources